Cancer

February 19, 2019

Combinatorial therapy for prostate cancer:  A therapeutic mix encompassing  Simvastatin and Navitoclax/ABT-263 (SAN) inhibits the expression of mTORC1 and its downstream target AMD1, dismantles mTORC1-AMD1 signaling network, decreases polyamine levels, and inhibits prostate cancer progression via up regualtion of its target gene, 20/February/2019, 12.09 am

Introduction: What they say: A study from CIC bioGUNE (Center for Cooperative Research in Biosciences), Bizkaia Technology Park, 801 Building, 48160 Derio, Spain shows that “mTORC1-dependent AMD1 regulation sustains polyamine […]
February 19, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing  Fenofibrate and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, TIMP3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 19/February/2019, `3.13 pm

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that:  Probiotic-based chemotherapy targeting cancer stem […]
February 18, 2019

Combinatorial therapy for glioblastoma: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) [SAN] inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down-regulation of its target gene, 18/February/2019, 1.07 pm

Introduction: What they say:  A study from the Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Ohio, USA shows that “Transcription elongation factors […]
February 18, 2019

Combinatorial therapy for drug-resistant cancers: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) (SAN) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via upregulation of its target gene, 18/February/2019, 12.49 pm

Introduction: What they say: A study from Broad Institute, Cambridge, Massachusetts, USA, Howard Hughes Medical Institute, Chevy Chase, Maryland and Department of Chemistry and Chemical Biology, […]